PHILADELPHIA INQUIRER — Monoclonal antibodies are not magic bullets. They must be given intravenously in a hospital or infusion center where COVID-19 poses a particular danger to immune-compromised chemotherapy patients. HPM's Walid Gellad summarizes “We don’t want people running to the emergency room to get this therapy. We don’t want people running to infusion centers, where there are patients with cancer."
TRIB LIVE - HPM's Julie Donohue said certain protocols are critical to stemming potential transmission, naming strategies such as universal mask-wearing, heightened sanitizing and hygiene practices, and “cohorting”—dividing students and staff into distinct groups with minimal interaction between each other—to reduce their number of contacts throughout the day. “It’s an incredibly challenging set of decisions to make,”
MOUNTAIN STATE SPOTLIGHT - As COVID-19 deaths and hospitalizations in West Virginia are rising and the holidays loom, the worst may be ahead. Regardless of all else, the most important thing going forward is our individual behaviors, said Mark Roberts, chairman of health policy and management.
"I am fortunate to truly enjoy my work, as I have come to realize that not everyone can honestly say the same. Two things excite me. First, I look for stories in healthcare data. I get to identify variation in clinical, operational, and financial performance at hospitals and dig deep into their data to create actionable insights that drive change. Second, I manage and develop a broad staff. I get to be somewhat of a chameleon to harness their va...
TRIB LIVE - Findings from a research team led by HPM's Coleman Drake provide evidence that expanding insurance coverage is a potential avenue to improve cancer outcomes. “It’s really about getting people into the normal health care system rather than presenting at the ED (emergency department) or some other environment when things go wrong,” Drake said. “It allows people to access preventive health care.”
NATURE - Critical-care physician Derek Angus (BCHS ’92) of the University of Pittsburgh says that his hospital’s statistics team also saw reductions over time. “Without question, we’ve noticed a drop in mortality,” says Angus. “All things being equal, patients have a better chance of getting out alive.”
NEW YORK TIMES - “It’s kind of the best times for these therapies to enter, because they can have an impact,” said HPM's Walid F. Gellad, who leads Pitt's Center for Pharmaceutical Policy and Prescribing. “It’s also the worst time because we don’t have enough doses, and it’s going to add to the backlog of testing.”
BLOOMBERG LAW - The future of Covid-19 treatment research is cloudier after the FDA approved Gilead Sciences Inc.'s remdesivir. The approval solidifies the standard of care for hospitalized virus patients in the U.S. Shortages of remdesivir could slow down the development of other new Covid-19 drugs that might now be required to use it in their clinical trials. The approval doesn’t necessarily block other virus treatments from being authorized, ...
AXIOS - "We have an emergency use authorization that I want to get signed immediately," Trump said in a video Thursday. "The problem is every therapy for coronavirus has become politicized—every single therapy, and that's the last thing you want in a pandemic, so this is just next in line," said the Department of Health Policy and Management's Walid Gellad , director of the Center for Pharmaceutical Policy and Prescribing at the University of P...
PHILADELPHIA TRIBUNE - Nearly 8,000 COVID-19 deaths have been confirmed in Pennsylvania. Had fewer restrictions been imposed, that toll likely would have been several times higher, said Mark Roberts, director of the Public Health Dynamics Lab. “It’s easy to project that there would be two to three times the deaths, at a minimum, with less social distancing.” His team developed a model to estimate the impacts of closings and reopenings.
WBHM - This proof-of concept study suggests that the strategy of blocking virus with antibodies holds promise. Inmaculada “Inma” Hernandez (HPM ’16), Pitt School of Pharmacy, is hopeful, but she doubts that these drugs will be a game-changer. “These drugs are so complex to produce, probably we will not have antibodies available for treating everybody who gets coronavirus. They’re probably going to be considerably expensive.”
TRIBUNE-DEMOCRAT – “We are concerned that policymakers may have interpreted the one-year downturn in 2018 as evidence for an especially effective national response or the start of a long-term trend,” said lead author Hawre Jalal, HPM. “Unfortunately, that isn’t supported by the data.” The data suggests there has been a 5.6 percent increase in fatal overdoses nationwide since 2018.
PITTSBURGH POST-GAZETTE - "We had a pretty good early run," said HPM Chair Mark Roberts, director of the Public Health Dynamics Lab. "If you look at the graph of cases over time, back in April, we were doing pretty well with surprisingly few cases." The peak day of the early months of COVID-19 came with 73 new cases on April 3 - a number that would be considered an average day today.
WASHINGTON POST – HPM's Tina Batra Hershey agrees that there's a need for executive administrations to “provide clear and transparent communications about what they’re doing, to ensure that there is a tailored response.” That might mean articulating what steps will be taken to measure whether restrictions are working and when they can be lifted, she said. “I think the judiciary will require more from the executive.”
HPM's Mark Roberts has been appointed to the rank of Distinguished Professor at the University of Pittsburgh. Professor Roberts is Chair, Department of Health Policy and Management and Director of the Public Health Dynamics Laboratory (PHDL). In addition to his academic appointments, Dr. Roberts has held many administrative appointments, such as Director of the Institute of Clinical Research Education (ICRE) from 2007 to 2010, Senior Medical Dir...